Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Altastaph in S. aureus Bacteremia
NCT00063089Phase 2Completed
- Sponsor
- Nabi Biopharmaceuticals
- Start
- Sep 2002
- Primary completion
- Sep 2004
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in Staphylococcus aureus bacteremia (SAB) comparing Altastaph with Placebo (2 arms). Primary endpoint: Safety at 6 weeks. Started Sep 2002; status: completed.
02
Drugs
altastaph
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT00063089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063089.